231 related articles for article (PubMed ID: 21804136)
1. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.
Ayuzawa N; Ishibashi Y; Takazawa Y; Kume H; Fujita T
Perit Dial Int; 2012; 32(2):159-67. PubMed ID: 21804136
[TBL] [Abstract][Full Text] [Related]
2. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology.
Honda K; Hamada C; Nakayama M; Miyazaki M; Sherif AM; Harada T; Hirano H;
Clin J Am Soc Nephrol; 2008 May; 3(3):720-8. PubMed ID: 18272828
[TBL] [Abstract][Full Text] [Related]
3. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients.
Tawada M; Hamada C; Suzuki Y; Sakata F; Sun T; Kinashi H; Katsuno T; Takei Y; Maruyama S; Honda K; Mizuno M; Ito Y
Clin Exp Nephrol; 2019 May; 23(5):689-699. PubMed ID: 30547267
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients.
Nakamoto H; Hamada C; Shimaoka T; Sekiguchi Y; Io H; Kaneko K; Horikoshi S; Tomino Y
J Artif Organs; 2014 Mar; 17(1):60-8. PubMed ID: 24337623
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
7. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
8. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
9. Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies.
del Peso G; Jiménez-Heffernan JA; Selgas R; Remón C; Ossorio M; Fernández-Perpén A; Sánchez-Tomero JA; Cirugeda A; de Sousa E; Sandoval P; Díaz R; López-Cabrera M; Bajo MA
Perit Dial Int; 2016; 36(2):129-34. PubMed ID: 26475848
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
11. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats.
Ikehara O; Nishimura H; Naito T; Higuchi C; Sanaka T
Nephron Exp Nephrol; 2005; 100(1):e30-9. PubMed ID: 15731567
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions.
Williams JD; Craig KJ; Topley N; Williams GT
Kidney Int Suppl; 2003 May; (84):S158-61. PubMed ID: 12694335
[TBL] [Abstract][Full Text] [Related]
13. Recent Understanding of Peritoneal Pathology in Peritoneal Dialysis Patients in Japan.
Hamada C; Tomino Y
Blood Purif; 2021; 50(6):719-728. PubMed ID: 33567422
[TBL] [Abstract][Full Text] [Related]
14. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.
Sugiyama N; Tawada M; Sun T; Suzuki Y; Kinashi H; Yamaguchi M; Katsuno T; Aten J; Vlahu CA; van Kuppevelt TH; Takei Y; Ishimoto T; Maruyama S; Mizuno M; Ito Y
Clin Exp Nephrol; 2021 Sep; 25(9):1035-1046. PubMed ID: 33999275
[TBL] [Abstract][Full Text] [Related]
15. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
Higuchi C; Nishimura H; Sanaka T
Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
[TBL] [Abstract][Full Text] [Related]
16. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
17. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
18. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
19. Histologic change of peritoneal membrane in relation to adequacy of dialysis in continuous ambulatory peritoneal dialysis patients.
Savidaki I; Karavias D; Sotsiou F; Alexandri S; Kalliakmani P; Presvelos D; Papachristou E; Goumenos DS; Vlachojannis JG
Perit Dial Int; 2003 Dec; 23 Suppl 2():S26-30. PubMed ID: 17986552
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for encapsulating peritoneal sclerosis: Analysis of a 36-year experience in a University Hospital.
Nakao M; Yamamoto I; Maruyama Y; Morishita M; Nakashima A; Matsuo N; Tanno Y; Ohkido I; Ikeda M; Yamamoto H; Yokoyama K; Yokoo T
Nephrology (Carlton); 2017 Nov; 22(11):907-912. PubMed ID: 27556577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
